Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1α under normoxic condition

Cancer Letters

Volumn 303, Issue 2, 2011, Pages 108-117

  Zhang, Min ^a   Ma, Qingyong ^a   Hu, Hengtong ^a   Zhang, Dong ^a   Li, Junhui ^a   Ma, Guodong ^a   Bhat, Kruttika ^b   Wu, Erxi ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

HIF 1 ; Invasion; Normoxia; Pancreatic cancer; SCF c kit

Indexed keywords

GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; SMALL INTERFERING RNA; STEM CELL FACTOR; UROKINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANOXIA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM INVASIVENESS; OXYGEN; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 79952040479     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.017     Document Type: Article

References (46)

1. Huizinga J.D., Thuneberg L., Kluppel M., Malysz J., Mikkelsen H.B., Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373:347-349.
2. Kitamura Y., Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979, 53:492-497.
3. Nocka K., Buck J., Levi E., Besmer P. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. The EMBO Journal 1990, 9:3287-3294.
4. Geissler E.N., Ryan M.A., Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988, 55:185-192.
5. Ashman L.K. The biology of stem cell factor and its receptor c-kit. The International Journal of Biochemistry and Cell Biology 1999, 31:1037-1051.
6. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L., Hsu R.Y., Birkett N.C., Okino K.H., Murdock D.C., et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990, 63:213-224.
7. Williams D.E., Eisenman J., Baird A., Rauch C., Van Ness K., March C.J., Park L.S., Martin U., Mochizuki D.Y., Boswell H.S., et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990, 63:167-174.
8. Huang E., Nocka K., Beier D.R., Chu T.Y., Buck J., Lahm H.W., Wellner D., Leder P., Besmer P. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990, 63:225-233.
9. Witte O.N. Steel locus defines new multipotent growth factor. Cell 1990, 63:5-6.
10. Blume-Jensen P., Claesson-Welsh L., Siegbahn A., Zsebo K.M., Westermark B., Heldin C.H. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. The EMBO Journal 1991, 10:4121-4128.
11. Lennartsson J., Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Current Cancer Drug Targets 2006, 6:65-75.
12. Nio Y., Omori H., Toga T., Hashimoto K., Itakura M., Koike M., Yano S., Higami T. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. Anti-Cancer Drugs 2003, 14:313-319.
13. Yasuda A., Sawai H., Takahashi H., Ochi N., Matsuo Y., Funahashi H., Sato M., Okada Y., Takeyama H., Manabe T. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Molecular Cancer 2006, 5:46.
14. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in Molecular Medicine 2002, 8:S62-67.
15. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. The American Journal of Pathology 2000, 157:411-421.
16. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Reviews 2003, 3:721-732.
17. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
18. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
19. Stiehl D.P., Wirthner R., Koditz J., Spielmann P., Camenisch G., Wenger R.H. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. The Journal of Biological Chemistry 2006, 281:23482-23491.
20. Zhong H., Mabjeesh N., Willard M., Simons J. Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Letters 2002, 181:233-238.
21. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., Niizeki H., Kawamura K., Hosokawa M., Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Research 2001, 61:6548-6554.
22. Chan D.A., Sutphin P.D., Denko N.C., Giaccia A.J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. The Journal of Biological Chemistry 2002, 277:40112-40117.
23. Ali S., Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007, 401:38-45.
24. Liu L., Ning X., Han S., Zhang H., Sun L., Shi Y., Sun S., Guo C., Yin F., Qiao T., Wu K., Fan D. Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cell: involvement of ERK1/2 and PI3K/Akt. Molecular Biology 2008, 42:459-469.
25. Yang X.M., Wang Y.S., Zhang J., Li Y., Xu J.F., Zhu J., Zhao W., Chu D.K., Wiedemann P. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Investigative Ophthalmology and Visual Science 2009, 50:1873-1879.
26. Langley K.E., Bennett L.G., Wypych J., Yancik S.A., Liu X.D., Westcott K.R., Chang D.G., Smith K.A., Zsebo K.M. Soluble stem cell factor in human serum. Blood 1993, 81:656-660.
27. Kojima S., Matsuyama T., Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. British Journal of Haematology 1997, 99:440-446.
28. Kitoh T., Ishikawa H., Ishii T., Nakagawa S. Elevated SCF levels in the serum of patients with chronic renal failure. British Journal of Haematology 1998, 102:1151-1156.
29. Kwon S.J., Lee Y.J. Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clinical Cancer Research 2005, 11:4694-4700.
30. Li Q.F., Wang X.R., Yang Y.W., Lin H. Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in lung epithelial cells: characterization and comparison with HIF-1alpha. Cell Research 2006, 16:548-558.
31. Wang V., Davis D.A., Haque M., Huang L.E., Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Research 2005, 65:3299-3306.
32. Miyoshi A., Kitajima Y., Ide T., Ohtaka K., Nagasawa H., Uto Y., Hori H., Miyazaki K. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. International Journal of Oncology 2006, 29:1533-1539.
33. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-kit. Cellular and Molecular Life Sciences 2004, 61:2535-2548.
34. Jubb A.M., Pham T.Q., Hanby A.M., Frantz G.D., Peale F.V., Wu T.D., Koeppen H.W., Hillan K.J. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. Journal of Clinical Pathology 2004, 57:504-512.
35. Treins C., Giorgetti-Peraldi S., Murdaca J., Monthouel-Kartmann M.N., Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Molecular Endocrinology 2005, 1304-1317.
36. Shi Y.H., Wang Y.X., Bingle L., Gong L.H., Heng W.J., Li Y., Fang W.G. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. The Journal of Pathology 2005, 205:530-536.
37. Alam H., Weck J., Maizels E., Park Y., Lee E.J., Ashcroft M., Hunzicker-Dunn M. Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology 2009, 150:915-928.
38. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochemical Pharmacology 2002, 64:993-998.
39. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V., Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. The Journal of Biological Chemistry 2003, 278:14013-14019.
40. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth and Differentiation 2001, 12:363-369.
41. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., Remacle J., Michiels C. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Letters 2000, 468:53-58.
42. Liu C., Shi Y., Du Y., Ning X., Liu N., Huang D., Liang J., Xue Y., Fan D. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Experimental Cell Research 2005, 309:410-418.
43. Nabeshima K., Inoue T., Shimao Y., Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathology International 2002, 52:255-264.
44. Schelter F., Gerg M., Halbgewachs B., Schaten S., Gorlach A., Schrotzlmair F., Kruger A. Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. The Journal of Biological Chemistry 2010, 285:26182-26189.
45. Liu L., Sun L., Zhao P., Yao L., Jin H., Liang S., Wang Y., Zhang D., Pang Y., Shi Y., Chai N., Zhang H., Zhang H. Hypoxia promotes metastasis in human gastric cancer by up-regulating the 67-kDa laminin receptor. Cancer Science 2010, 101:1653-1660.
46. Kindler H.L. Front-line therapy of advanced pancreatic cancer. Seminars in Oncology 2005, 32:S33-S36.